Table 4.
Biomarkers at Baseline and after 6-Months in the Two Treatment Groups.
| Placebo T0 | Placebo T2 | PlaT0-T2 | Probiotic T0 | Probiotic T2 | Pro T0-T2 | p ANOVA Pla/ProT0 | p ANOVA Pla/Pro T0-T2 | |
|---|---|---|---|---|---|---|---|---|
| mean(SD) | mean(SD) | mean(SD) | mean(SD) | |||||
| Plasmatic Biomarkers | ||||||||
|
IL-6
pg/ml |
3.61 (6.18) | 3.54 (3.63) | -0.08 | 3.24 (4.32) | 3.33 (2.63) | 0.09 | ns | ns |
|
Leptin
pg/ml |
1.21 (1.03) | 1.32 (1.09) | 0.11 | 1.23 (0.82) | 1.13 (0.96) | -0.10 | ns | ns |
|
TNF-α
pg/ml |
6.47 (2.79) | 6.16 (2.34) | -0.32 | 5.45 (2.14) | 5.82 (2.16) | 0.37 | ns | ns |
|
PAI-1
ng/ml |
28.79 (23.20) | 27.31 (12.54) | -1.48 | 28.34 (18.15) | 32.46 (23.86) | 4.11 | ns | ns |
| Fecal Biomarker | ||||||||
|
Calprotectin
μgr/gr |
128.43 (171.87) | 204.61 (438.11) | +76.18 | 138.12 (196.32) | 129.50 (139.67) | -8.62 | ns | ns |
IL-6, interleukin-6; PAI 1, Plasminogen Activator Inhibitor-1; TNF-α, Tumor Necrosis Factor-alpha; ns, not significant.